Identification of methylation sites and signature genes with prognostic value for luminal breast cancer

Xiao, Bin; Chen, Lidan; Ke, Yong-Li; Hang, Jianfeng; Cao, Lu; Zhang, Rong; Zhang, Weiyun; Liao, Yang; Gao, Yang; Chen, Jianyun; Li, Li; Hao, Wenbo; Sun, Zhigang

doi:10.1186/s12885-018-4314-9

Cited by 49 publications

(62 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ESCO2 is highly expressed in aggressive melanomas and breast cancer. 14 , 15 In gastric cancer, ESCO2 promoted cell proliferation by modulating p53 and mammalian target of rapamycin (mTOR) signaling pathways. 16 However, the biological function and clinical significance of ESCO2 in CRC remain unclear.…”

Section: Introductionmentioning

confidence: 99%

ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancer

Guo¹,

Huang²,

Pan³

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundEstablishment of cohesion 1 homolog 2 (ESCO2) plays important roles in the regulation of cohesion and genomic stability and has been implicated in human cancers. Yet, its clinical significance and biological function in colorectal cancer (CRC) are unknown.MethodsThe expression of ESCO2 was examined by quantitative real-time PCR, Western blot, and immunohistochemistry. The role of ESCO2 in the tumor metastasis of CRC and the related mechanisms were investigated using in vitro and in vivo models.ResultsIn this study, we show that low expression of ESCO2 in CRC was closely correlated with lymphatic and distant metastasis. Patients with low ESCO2 expression experienced shorter overall survival and disease-free survival in two independent cohorts containing a total of 587 CRC cases. ESCO2 overexpression suppressed, whereas ESCO2 knockdown promoted cell migration in vitro and tumor metastasis in vivo via modulation of epithelial–mesenchymal transition (EMT) process. Mechanistically, ESCO2 inhibited the transcriptional activity of MMP2 promoter to downregulate its expression. Reexpression of MMP2 partially attenuated the ESCO2-mediated malignant phenotypes.ConclusionCollectively, our data suggest that ESCO2 serves as a potential prognostic factor and exerts antimetastatic activity in CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancer

Guo¹,

Huang²,

Pan³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…Being able to capture and analyze these unique invading subpopulations in the act of doing so, together with their matched non-invasive counterparts, will be key in making progress towards understanding and treating cancer. While much work has been done in this field, some of these studies compare between different patients or utilize cell lines of different invasive properties [10][11][12][13][14] , which may be confounded by existing inter-tumor heterogeneity. While there have been other reports studying spatial heterogeneity within patient samples, these studies utilized the use of formalin fixed primary tumor tissue for the identification of genomic markers 15,16 .…”

mentioning

confidence: 99%

Heterogeneity at the invasion front of triple negative breast cancer cells

Yong

Ulintz

Cáceres

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Identifying better predictive and prognostic biomarkers for the diagnosis and treatment of triple negative breast cancer (TNBC) is complicated by tumor heterogeneity ranging from responses to therapy, mutational burden, and clonal evolution. To overcome the gap in our understanding of tumor heterogeneity, we hypothesized that isolating and studying the gene expression profile of invasive tumor cell subpopulations would be a crucial step towards achieving this goal. In this report, we utilized a fluidic device previously reported to be capable of supporting long-term three-dimensional growth and invasion dynamics of cancer cells. Live invading and matched non-invading SUM149 inflammatory breast cancer cells were enriched using this device and these two functionally distinct subpopulations were tested for differences in gene expression using a gene expression microarray. 305 target genes were identified to have altered expression in the invading cells compared to the non-invading tumoroid cells. Gene ontology analysis of the gene panel identified multiple biological roles ranging from extracellular matrix reorganization to modulation of the immune response and Rho signaling. Interestingly, the genes associated with the invasion front differ between different samples, consistent with inter- and intra-tumor heterogeneity. This work suggests the impact of heterogeneity in biomarker discovery should be considered as cancer therapy increasingly heads towards a personalized approach.

show abstract

“…Recent study demonstrated that CDCA2 promoted colorectal cancer cells proliferation by activating the AKT/CCND1 pathway in vitro and in vivo [11]. More studies were carried out to identify that CDCA could be an signature gene with prognostic value for luminal breast cancer, esophageal squamous cell carcinoma, bladder cancer, melanoma and Synovial sarcoma [12,13,21,23]. In this work, we also demonstrated that strong expression of CDCA2 in glioma was associated with advanced clinical pathologic characteristics and higher expression of CDCA2 was an an independent prognostic indicator associated with poor survival in glioma.…”

Section: Discussionmentioning

confidence: 99%

Increased Expression of CDCA2 in Glioma Predicts Poor Prognosis as Identified by Population-based Analysis

Dong¹,

Liu²

2020

Preprint

View full text Add to dashboard Cite

Background: The cell division cycle-associated protein 2 (CDCA2) was found to be a cell cycle-related protein. CDCA2 was previously reported to be associated with proliferation and migration in multiple cancer. We evaluated the role of CDCA2 in glioma using publicly available data from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA).Methods: The relationships between clinical characteristics and CDCA2 expression were analyzed using the Wilcoxon test or Kruskal-Wallis test. Clinicopathologic characteristics associated with overall survival (OS) were analyzed using Cox regression analysis and Kaplan-Meier method. Gene Set Enrichment Analysis (GSEA) was performed to sort the signaling pathway associated with the expression of CDCA2. Pearson correlation test was used to analyse the expression correlation between CDCA2 and well-known cell cycle-related genes.Results: Glioma with high CDCA2 expression was more prone to be associated with advanced malignancy clinical pathologic characteristics and worse prognosis than that with low CDCA2 expression in TCGA and CGGA dataset (P < 0.001). The multiple analysis revealed that CDCA2 was independently associated with OS (HR:1.396; [CI]:1.236 − 1.577, P < 0.001). GSEA showed that cell cycle checkpoint, cell cycle G1/S phase transition, DNA damage checkpoint and regulation of cell cycle arrest were enriched in CDCA2 high expression phenotype. Pearson correlation test revealed that CDCA2 was co-expression with well-known key cell cycle-related genes (CCNA2, CCNB1, CCNB2, CCNE1, CCNE2, CDK1, CDK2, CDK4, CDK6).Conclusion: High CDCA2 expression may be a potential prognosis molecular marker of poor survival in glioma. Cell cycle regulation pathway may be the key pathway regulated by CDCA2 in glioma.

show abstract

Identification of methylation sites and signature genes with prognostic value for luminal breast cancer

Cited by 49 publications

References 43 publications

ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancer

ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancer

Heterogeneity at the invasion front of triple negative breast cancer cells

Increased Expression of CDCA2 in Glioma Predicts Poor Prognosis as Identified by Population-based Analysis

Contact Info

Product

Resources

About